Selected article for: "affinity purification and human cell"
Author: David E. Gordon; Gwendolyn M. Jang; Mehdi Bouhaddou; Jiewei Xu; Kirsten Obernier; Matthew J O'Meara; Jeffrey Z. Guo; Danielle L. Swaney; Tia A. Tummino; Ruth Huttenhain; Robyn Kaake; Alicia L. Richards; Beril Tutuncuoglu; Helene Foussard; Jyoti Batra; Kelsey Haas; Maya Modak; Minkyu Kim; Paige Haas; Benjamin J. Polacco; Hannes Braberg; Jacqueline M. Fabius; Manon Eckhardt; Margaret Soucheray; Melanie Brewer; Merve Cakir; Michael J. McGregor; Qiongyu Li; Zun Zar Chi Naing; Yuan Zhou; Shiming Peng; Ilsa T. Kirby; James E. Melnyk; John S Chorba; Kevin Lou; Shizhong A. Dai; Wenqi Shen; Ying Shi; Ziyang Zhang; Inigo Barrio-Hernandez; Danish Memon; Claudia Hernandez-Armenta; Christopher J.P. Mathy; Tina Perica; Kala B. Pilla; Sai J. Ganesan; Daniel J. Saltzberg; Rakesh Ramachandran; Xi Liu; Sara B. Rosenthal; Lorenzo Calviello; Srivats Venkataramanan; Yizhu Lin; Stephanie A. Wankowicz; Markus Bohn; Phillip P. Sharp; Raphael Trenker; Janet M. Young; Devin A. Cavero; Joseph Hiatt; Theo Roth; Ujjwal Rathore; Advait Subramanian; Julia Noack; Mathieu Hubert; Ferdinand Roesch; Thomas Vallet; Björn Meyer; Kris M. White; Lisa Miorin; Oren S. Rosenberg; Kliment A. Verba; David Agard; Melanie Ott; Michael Emerman; Davide Ruggero; Adolfo Garcí-Sastre; Natalia Jura; Mark von Zastrow; Jack Taunton; Olivier Schwartz; Marco Vignuzzi; Christophe d'Enfert; Shaeri Mukherjee; Matt Jacobson; Harmit S. Malik; Danica G Fujimori; Trey Ideker; Charles S Craik; Stephen Floor; James S. Fraser; John Gross; Andrej Sali; Tanja Kortemme; Pedro Beltrao; Kevan Shokat; Brian K. Shoichet; Nevan J. Krogan
Title: A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
  • Document date: 2020_3_22
    • ID: 38d6gb7o_7
    Snippet: Our affinity purification-mass spectrometry analysis identified 332 protein interactions between SARS-CoV-2 proteins and human proteins (Extended Data Fig. 1 , Supplementary Tables 1, 2 ; also see Fig. 3 ). We studied the interacting human proteins in regards to their cell biology, anatomical expression patterns, expression changes during SARS-CoV-2 infection 21 and in relation to other maps of pathogen interacting proteins 19, [22] [23] [24] [25.....
    Document: Our affinity purification-mass spectrometry analysis identified 332 protein interactions between SARS-CoV-2 proteins and human proteins (Extended Data Fig. 1 , Supplementary Tables 1, 2 ; also see Fig. 3 ). We studied the interacting human proteins in regards to their cell biology, anatomical expression patterns, expression changes during SARS-CoV-2 infection 21 and in relation to other maps of pathogen interacting proteins 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] (Fig. 2a) . For each of the viral proteins, we performed Gene Ontology enrichment analysis (Fig. 2b , Extended Data Fig. 2) , identifying the major cell biological processes of the interacting proteins, including lipoprotein metabolism (S), nuclear transport (Nsp7), and biogenesis of ribonucleoprotein (Nsp8). To discover potential binding interfaces, we performed an enrichment for domain families within the interacting proteins of each viral bait (Extended Data Fig. 3) . As examples, we note the enrichment of DNA polymerase domains in the interactors of Nsp1 and the enrichment of bromodomains and extra-terminal domain (BET) family for interactors of E (see also Figs. 3, 4) . In line with the latter, the interactors of E are also enriched in genes annotated for binding to acetylated histones (Fig. 2b) .

    Search related documents:
    Co phrase search for related documents
    • affinity purification mass spectrometry analysis and purification mass: 1, 2, 3, 4, 5, 6
    • affinity purification mass spectrometry analysis and purification mass spectrometry: 1, 2, 3, 4, 5, 6
    • affinity purification mass spectrometry analysis and SARS protein: 1, 2
    • affinity purification mass spectrometry analysis and viral protein: 1, 2
    • affinity purification mass spectrometry and cell biology: 1
    • affinity purification mass spectrometry and enrichment analysis: 1
    • affinity purification mass spectrometry and human protein: 1, 2, 3, 4, 5, 6, 7
    • affinity purification mass spectrometry and human protein SARS protein: 1, 2
    • affinity purification mass spectrometry and interact protein: 1, 2, 3, 4
    • affinity purification mass spectrometry and protein interaction: 1, 2, 3, 4, 5
    • affinity purification mass spectrometry and purification mass: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
    • affinity purification mass spectrometry and purification mass spectrometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
    • affinity purification mass spectrometry and SARS infection: 1, 2, 3, 4
    • affinity purification mass spectrometry and SARS protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • affinity purification mass spectrometry and viral protein: 1, 2, 3, 4, 5, 6, 7, 8